| (USD) | Mar 2024 | Q/Q |
|---|---|---|
| Revenue | 6.7B | -6% |
| Gross Profit | 5.1B | - |
| Cost Of Revenue | 1.6B | -26% |
| Operating Income | -4.3B | -368% |
| Operating Expenses | 9.5B | - |
| Net Income | -4.2B | -392% |
| R&D | 1.5B | +8% |
| G&A | 1.4B | -14% |
| Amortization | - | - |
| Interest Expense | 254MM | +1% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
NORTHAMPTON, MA / ACCESSWIRE / May 7, 2024 / James had been free from using drugs for a decade when a routine test at his local health center revealed he had hepatitis C (HCV). James was one of many people in the island nation of Mauritius to receive ...
FOSTER CITY, Calif. & SANTA MONICA, Calif., May 07, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 18 abstracts during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. These data showcase the ongoing commitment to developing differentiated approaches to transform how cancer is treated and span solid tumors and blood cancers, including lung, breast, gastrointestinal, colorectal, leukemia and lymphoma.
In this article, we discuss the 23 most profitable stocks of the last 12 months. If you want to skip our detailed analysis of these stocks, go directly to 5 Most Profitable Stocks of the Last 12 Months. The United States stock market has come a long way since the turn of the millennium more […]
NORTHAMPTON, MA / ACCESSWIRE / May 3, 2024 / Gilead Sciences Forbes has listed Gilead as one of America's Best Employers for Diversity. We believe that by championing inclusion and diversity, we not only enrich our workplace but also drive groundbreaking ...
Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine are included in this Analyst Blog.
Deciphera Pharmaceuticals, Inc. (DCPH) and GSK are in focus on acquisition news and Q1 earnings, respectively.
Biotech stocks are full of intriguing innovators who could help pave the way for greater gains over the years ahead. Undoubtedly, it’s virtually impossible to tell exactly which pills, shots and treatments within a firm’s pipeline will eventually evolve into cash flows, let alone blockbuster cash cows. With many clinical trials to pass, even a promising late-stage candidate can still fall flat. Biotech investors may wish to play the odds game regarding a biotech innovator’s pipeline. Some treatm
FOSTER CITY, Calif., April 30, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:
Gilead Sciences, Inc. (NASDAQ:GILD) Q1 2024 Earnings Call Transcript April 25, 2024 Gilead Sciences, Inc. beats earnings expectations. Reported EPS is $-1.32, expectations were $-1.49. Gilead Sciences, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, everyone, and […]
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.